Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Understanding and Appraising the New Medicine Service in England
Brief Summary: About 25% medicines prescribed for long term conditions are not taken as directed, and approximately 15% people receiving a new medicine take few, if any, doses. The New Medicine Service (NMS) is a community pharmacy service that started in England in October 2011 which involves the pharmacist providing additional support to patients starting a new medicine for some breathing problems (asthma \& COPD), high blood pressure, adult onset diabetes or medicines which reduce blood clotting. It aims to improve the way patients take their medicines improving outcomes and reducing costs to the National Health Service (NHS).

The investigators will assess the effectiveness and cost effectiveness of the NMS using a research study where some people will receive the NMS, and some won't, so The investigators can look at the effect of the NMS on problems with their medicines, medicines taking and use of the NHS in general. Data will be collected in the East Midlands, South Yorkshire and London areas.

The investigators will recruit 500 patients from a range of different pharmacies and follow them up at six, ten and twenty six weeks after starting their new medicine to assess effects on medicines taking behaviour, patients' reported problems with medicines, referrals to their General Practitioner (GP) and use of NHS resources. The investigators will compare the data gathered from this study with that being collected routinely by all pharmacies in England to provide wider estimates of cost effectiveness.

The investigators will also explore how the NMS service is being implemented by pharmacies. A sample of patients from the main study will be followed in more detail. This will involve recording the consultations with the pharmacist and also interviewing patients about their experience of the service. The investigators will interview the patients GP to investigate their views of the service. The investigators will also try to understand why people decline the invitation for the NMS


Options:
A: Arm Label: NMS; Type: EXPERIMENTAL; Interventions: Other: New Medicine Service | Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New Medicine Service; Assigned to Arm(s): NMS
B: Intervention Type: DRUG; Name: Formoterol Fumurate inhalation solution 20 mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg; Assigned to Arm(s): N/A
C: Arm Label: MF/F MDI 100/10 mcg BID with dose counter; Type: EXPERIMENTAL; Interventions: Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ) | Intervention Type: DRUG; Name: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ); Assigned to Arm(s): MF/F MDI 100/10 mcg BID with dose counter
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: adherence to guideline; Type: OTHER; Interventions: Other: Implementation educational programme | Intervention Type: OTHER; Name: Implementation educational programme; Assigned to Arm(s): adherence to guideline

Answer: A